Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Pulmonary Embolism III: Nursing Management

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An improved method for differentiating acid-forming from non-acid-forming bacteria.

Journal of bacteriology·2010

Same author

Continuing the use of the Cockcroft-Gault equation for drug dosing in patients with impaired renal function.

Clinical pharmacology and therapeutics·2009

Same author

Health literacy and transplant patients and practitioners.

Public health·2007

Same author

Medicare Part D coverage and its influence on transplant patients' out-of-pocket prescription expenses.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2006

Same author

Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2002

Same author

Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2001

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Deep venous thrombosis prophylaxis in trauma: cost analysis.

W E Wade¹, M A Chisholm

¹College of Pharmacy, University of Georgia, Athens 30602, USA. BWADE@rx.uga.edu

Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis

|February 26, 2000

Summary

This summary is machine-generated.

Enoxaparin prophylaxis for trauma patients may cost $279.43 per event avoided. However, cost savings are possible if enoxaparin

More Related Videos

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

Rodent Inferior Vena Cava Venoplasty Balloon Model

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Related Experiment Videos

Last Updated: Jun 26, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Point-Of-Care Ultrasound Screening for Proximal Lower Extremity Deep Venous Thrombosis

Published on: February 10, 2023

Rodent Inferior Vena Cava Venoplasty Balloon Model

Rodent Inferior Vena Cava Venoplasty Balloon Model

Published on: May 24, 2024

Area of Science:

Trauma and Emergency Medicine
Pharmacoeconomics
Thromboembolic Disease Prevention

Background:

Major trauma patients face significant risks of deep vein thrombosis and pulmonary embolism.
Current guidelines recommend low molecular weight heparin (LMWH) for prophylaxis in high-risk trauma patients without contraindications.
Enoxaparin is the sole LMWH evaluated for this indication in the US.

Purpose of the Study:

To calculate the incremental cost-effectiveness ratio (ICER) of enoxaparin versus no prophylaxis for thromboembolic events in trauma patients.
To assess the economic impact of routine enoxaparin prophylaxis in this patient population.

Main Methods:

Incremental cost-effectiveness ratio (ICER) analysis.
Pharmacoeconomic modeling comparing enoxaparin prophylaxis to no prophylaxis.
Sensitivity analyses to evaluate key variables influencing cost-effectiveness.

Main Results:

Routine enoxaparin prophylaxis (30 mg every 12 hours) is associated with an estimated cost of $279.43 per thromboembolic event avoided.
Sensitivity analyses indicate potential cost savings under specific conditions: enoxaparin incidence of proximal vein thrombosis nearing 1.8%, untreated patient thrombosis rates exceeding 19.4%, or drug cost reduction to $15.25 per dose.

Conclusions:

Enoxaparin prophylaxis in major trauma patients presents a defined cost per event avoided.
The economic viability of enoxaparin prophylaxis is sensitive to drug costs and event incidence rates, suggesting potential for cost savings in certain scenarios.